Pipeline

Influenza

iQur is now working to develop a universal flu vaccine, testing it against antigens from all known strains of influenza A and influenza B.

Hepatitis C

iQur is in the early stages of developing a preventative vaccine for hepatitis C in collaboration with researchers at the University of Nottingham.

Other Assets

iQur’s VLP platform technology can also be utilised to generate monoclonal antibodies against epitopes which are otherwise difficult to target because there are cryptic or non-immunogenic.